As the upcoming Medicare drug pricing negotiations approach, the US Centers for Medicare and Medicaid Services (CMS) have released a revised guidance that better outlines the process. Pharma companies and industry groups have been anxiously awaiting such clarification, but the new information has done little to quell their concerns.
According to the guidance, “CMS will not publicly discuss ongoing negotiations prior to the release of the explanation of the maximum fair price (MFP) unless a (drug maker) publicly discloses information regarding the negotiation process. In addition, CMS will treat as proprietary certain data submitted by a (drug maker)”
To read more, click here.
(Source: Yahoo! Finance, June 30th, 2023)